148 related articles for article (PubMed ID: 24446536)
1. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Asbun-Bojalil J; Lira-Islas Y; Reyes-Ponce C; Guàrdia-Olmos J
Hum Psychopharmacol; 2012 Nov; 27(6):577-86. PubMed ID: 24446536
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.
Gudayol-Ferré E; Guàrdia-Olmos J; Peró-Cebollero M; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P
J Affect Disord; 2013 Sep; 150(3):1082-90. PubMed ID: 23787408
[TBL] [Abstract][Full Text] [Related]
3. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Cruz D; Hernández S; Genis A; Carrillo-Guerrero MY; Avilés Reyes R; Guàrdia-Olmos J
J Affect Disord; 2010 Dec; 127(1-3):343-51. PubMed ID: 20584552
[TBL] [Abstract][Full Text] [Related]
4. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.
Tsai SJ; Gau YT; Hong CJ; Liou YJ; Yu YW; Chen TJ
J Affect Disord; 2009 Feb; 113(1-2):183-7. PubMed ID: 18533273
[TBL] [Abstract][Full Text] [Related]
5. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
Manoharan A; Shewade DG; Rajkumar RP; Adithan S
Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
[TBL] [Abstract][Full Text] [Related]
6. Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive Disorder.
Camarena B; Álvarez-Icaza D; Hernández S; Aguilar A; Münch L; Martínez C; Becerra-Palars C
Clin Neuropharmacol; 2019; 42(1):9-13. PubMed ID: 30520759
[TBL] [Abstract][Full Text] [Related]
7. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
[TBL] [Abstract][Full Text] [Related]
8. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
9. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
Zou YF; Wang Y; Liu P; Feng XL; Wang BY; Zang TH; Yu X; Wei J; Liu ZC; Liu Y; Tao M; Li HC; Li KQ; Hu J; Li M; Zhang KR; Ye DQ; Xu XP
Hum Psychopharmacol; 2010 Mar; 25(2):145-52. PubMed ID: 20196181
[TBL] [Abstract][Full Text] [Related]
10. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
[TBL] [Abstract][Full Text] [Related]
11. SLC6A4 variation and citalopram response.
Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
[TBL] [Abstract][Full Text] [Related]
12. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.
Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E
Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660
[TBL] [Abstract][Full Text] [Related]
13. Association analysis of COMT/MTHFR polymorphisms and major depressive disorder in Chinese Han population.
Shen X; Wu Y; Guan T; Wang X; Qian M; Lin M; Shen Z; Sun J; Zhong H; Yang J; Li L; Yuan Y
J Affect Disord; 2014 Jun; 161():73-8. PubMed ID: 24751310
[TBL] [Abstract][Full Text] [Related]
14. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population.
Mandal T; Bairy LK; Sharma PSVN
Eur J Clin Pharmacol; 2020 Jun; 76(6):807-814. PubMed ID: 32253447
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Wong ML; Dong C; Flores DL; Ehrhart-Bornstein M; Bornstein S; Arcos-Burgos M; Licinio J
Am J Psychiatry; 2014 Dec; 171(12):1297-309. PubMed ID: 25220861
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
[TBL] [Abstract][Full Text] [Related]
17. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.
Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037
[TBL] [Abstract][Full Text] [Related]
18. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
[TBL] [Abstract][Full Text] [Related]
19. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
[TBL] [Abstract][Full Text] [Related]
20. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]